The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
SOPHARMA AD hereby informsthat from 15 September 2017 up to andincluding 18 September 2017 the Company bought 10 600 own shares representing 0.0079% of the share capital of the Company, at a total value of 44 878.01 BGN on the Bulgarian Stock Exchange, the average price per share was 4.23 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
Sopharma AD notifies that on 18 September 2017 Sopharma AD acquired 345 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.
SOPHARMA AD hereby informs that15 September 2017 the Company bought 15 695 own shares representing 0.011% of the share capital of the Company, at a total value of 67 954.41 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
SOPHARMA AD hereby informs that from 12 September 2017 up to and including 14 September 2017 the Company bought 50 000 own shares representing 0.037% of the share capital of the Company, at a total value of 222 085.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.44 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.